Article ID Journal Published Year Pages File Type
5825396 Clinical Therapeutics 2013 9 Pages PDF
Abstract
Considering the gross negative impact of the PLS on R&D investments of pharmaceutical firms and the heterogeneous response of these firms by the R&D activities, governmental efforts of cost-containment may need to consider the spillover impact of the PLS on pharmaceutical innovation.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Medicine and Dentistry (General)
Preview
Analyses of Direct and Indirect Impacts of a Positive List System on Pharmaceutical R&D Investments
Authors
, , , ,